Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Using R package to implement Bayesian phase I/II dose-finding design for three outcom

    Dear all,

    I am trying to implement the work done by Suyu Liu, "A Bayesian Phase I/II Trial Design for Immunotherapy", using R, since the code attached with that work takes a lot of time (more than 20 hours, and the code not complete). So that I tried to use trialr package since it used rstan, but this package allowed me to use two outcomes ( toxicity, efficacy ) and the work of Liu used three outcomes (immune response, toxicity, and efficacy).

    I tried to use the R package trialr for two outcomes using the utility for sensitivity analysis written in R code below (table 1 in the article), I want to see if I used the correct utility and to see how to add a third outcome ( immune response ) to the model

    and thanks in advance.

    Here is the work of Liu:



    ````

    ### My code###
    rm(list = ls())
    library(trialr)

    #Utility
    Uti <- array(0,c(2,3,2)) # order: tox, eff, immuno
    Uti[,,1] <- matrix(c(0,0,50,10,80,35),nrow=2)
    Uti[,,2] <- matrix(c(5,0,70,20,100,45),nrow=2)
    N.max= 60 # patients
    outcomes <- '1NNN 2NNT 3NNT 4NNN 5NTN'
    doses = c(.1,.3,.5,.7,.9)


    fit <- stan_efftox(outcomes,
    real_doses =doses,
    efficacy_hurdle = 0.5, toxicity_hurdle = 0.3,
    p_e = 0.1, p_t = 0.1,
    eff0 = 0.5, tox1 = 0.65,
    eff_star = 0.7, tox_star = 0.25,
    alpha_mean = -7.9593, alpha_sd = 3.5487,
    beta_mean = 1.5482, beta_sd = 3.5018,
    gamma_mean = 0.7367, gamma_sd = 2.5423,
    zeta_mean = 3.4181, zeta_sd = 2.4406,
    eta_mean = 0, eta_sd = 0.2,
    psi_mean = 0, psi_sd = 1,
    seed = 123)

    ndoses <- length(fit$prob_tox)
    plot(1:ndoses, fit$prob_tox, type="b", pch=19, xlab="Dose level", ylab="Probability of toxicity", ylim=c(0,max(fit$prob_tox) + 0.15), col="green")
    points(1:ndoses,fit$prob_eff, type="b", pch=18, col="blue")
    abline(h=0.3, lwd=2, lty=4, col = "red")
    legend(1, 0.4, legend=c("Toxicity", "Effecacy"),
    col=c("green", "blue"), lty=1:2, cex=0.8)

    ````

  • #2
    Thank you so much for this information; it’s really a very good information and very authentic and useful information for us. I really appreciate you have share this information.
    If you know more about this information just click here ptcl speed test and check more information with more reasonable and authentic way.

    Comment

    Latest Articles

    Collapse

    • seqadmin
      Essential Discoveries and Tools in Epitranscriptomics
      by seqadmin


      The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist on Modified Bases...
      Yesterday, 07:01 AM
    • seqadmin
      Current Approaches to Protein Sequencing
      by seqadmin


      Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
      04-04-2024, 04:25 PM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by seqadmin, 04-11-2024, 12:08 PM
    0 responses
    39 views
    0 likes
    Last Post seqadmin  
    Started by seqadmin, 04-10-2024, 10:19 PM
    0 responses
    41 views
    0 likes
    Last Post seqadmin  
    Started by seqadmin, 04-10-2024, 09:21 AM
    0 responses
    35 views
    0 likes
    Last Post seqadmin  
    Started by seqadmin, 04-04-2024, 09:00 AM
    0 responses
    55 views
    0 likes
    Last Post seqadmin  
    Working...
    X